Lung-targeted RNA delivery for safer lung therapies
Official title: Lung-targeting delivery of small interfering RNA for pulmonary therapeutics
Funded at Tiba Biotech, LLC · NIH-11408063 · Data updated 2026-11-12
A small early-stage NIH grant explores safer ways to deliver RNA-based medicines directly to the lungs to treat ARDS and related conditions.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tiba Biotech, LLC NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | August 1, 2026 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $396,805 |
| NIH project number | 1R43HL184887-01A1 |
| Project ID | NIH-11408063 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with ARDS/ALI or related acute lung conditions who might benefit from future lung-targeted RNA therapies.
✕Less likely to help
Patients not suffering from acute lung conditions may not directly benefit from this early-stage work.
What this research studies
This project looks at creating delivery methods for RNA therapies that reach the lungs specifically, aiming to reduce inflammation and off-target effects. It focuses on overcoming challenges of delivering nucleic acids to lung tissue without triggering harmful inflammatory responses. The work is designed to pave the way for future treatments that could help people with acute lung injury, ARDS, and other severe lung conditions. If successful, it could make RNA medicines safer and more effective for lung diseases.
Why it matters
Potential benefit: If successful, patients with ARDS or acute lung injury could benefit from safer, targeted RNA therapies that reach the lungs with fewer side effects.
How similar studies have gone: Prior RNA delivery studies show promise but respiratory-targeted, low-inflammation approaches remain experimental and early-stage.
Where this research is happening
-
Tiba Biotech, LLC
Cambridge, United States Active
Researchers
- Principal investigator: Chahal, Jasdave — Tiba Biotech, LLC
- Study coordinator: Chahal, Jasdave
Related research
Other NIH-funded projects on the same topics.
-
Fast multi-antigen mRNA vaccine for bird flu (H7N9)
This project is building a three-part mRNA vaccine meant to give quick, broad protection against the dangerous H7N9 bird flu for people at risk in future pandemics.
-
Developing a new RNA-based vaccine for avian influenza
This study is testing a new type of vaccine for the H7N9 bird flu virus, which can cause serious illness, to see if it can create a strong immune response with fewer side effects, and it's aimed at helping people stay safe during outbreaks.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.